Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Investor Newsletters
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Company and personnel

19 April 2017

GenSight Biologics to Attend Upcoming Investor Conferences

13 March 2017

GenSight Biologics Reports Full Year 2016 Financial Results

13 October 2016

GenSight Biologics reports its cash position as of September 30, 2016

11 August 2016

GenSight Biologics confirms the success of its IPO by exercising 88.9% of the over-allotment option

11 August 2016

GenSight Biologics announces the implementation of a liquidity contract with Oddo & Cie

13 July 2016

GenSight Biologics announces successful IPO on Euronext Paris

05 July 2016

GenSight Biologics launches its Initial Public Offering on the regulated market of Euronext in Paris

24 May 2016

GenSight Biologics announces the registration of its document de base in relation to its planned IPO on Euronext’s regulated market in Paris

23 July 2015

GenSight Biologics Closes $36 Million Series B Preferred Stock Financing

06 July 2015

GenSight Biologics Appoints Thomas Gidoin as Chief Financial Officer & Michael Wyzga to Board of Directors

  • View previous 9 articles
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • View next 9 articles
© 2025 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page